摘要
目的:观察尿激酶与依达拉奉联合治疗急性脑梗死的临床疗效。方法:将我院2008年3月-2010年3月期间收治的52例急性脑梗死患者随机均分为观察组和对照组。2组患者经明确诊断后均给予依达拉奉(30mg,bid)治疗,观察组在对照组的基础上加用尿激酶(20万U,qd)联合治疗,治疗前后比较2组的疗效、日常生活能力评分(ADL)及神经功能缺损评分(ESS)。结果:治疗后与对照组比较,观察组痊愈率和总有效率以及治疗后的ADL评分均明显提高,而治疗后的ESS评分则明显降低,2组比较差异均具有统计学意义(P<0.05)。2组均未见严重不良反应。结论:尿激酶与依达拉奉联合治疗急性脑梗死,其疗效确切,且不良反应少。
OBJECTIVE:To probe into the clinical efficacy of urokinase combined with edaravone in the treatment of acute cerebral infarction.METHODS:52 patients with acute cerebral infarction were selected from our hospital during Mar.2008-Mar.2010.Those patients were randomly divided into observation group and control group.2 groups were given edaravone(30 mg,bid),and observation group was additionally given urokinase(200 000 U,qd).The efficacy ADL and ESS were compared before and after treatment.RESULTS:Compared with control group,the cure rate,total effective rate and the activity of daily living scores in observation group were significantly improved while neurological deficit scores after treatment were significantly lowered,there were statistically significant difference(P0.05).There was no serious ADRs found in both groups.CONCLUSION:Urokinase combined with edaravone have remarkable curative effect on acute cerebral infarction.The ADRs is low.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第36期3419-3420,共2页
China Pharmacy
关键词
尿激酶
依达拉奉
急性脑梗死
Urokinase
Edaravone
Acute cerebral infarction